pharma · Solid Tumors · RAS Mutation · KTTA
Pasithea Therapeutics
Pasithea Therapeutics is a pharma organization headquartered in Miami Beach, USA. It trades on NYSE under ticker KTTA. Primary therapeutic focus areas include Solid Tumors, RAS Mutation, NF1 Mutation. NovaPharmaNews link
Miami Beach, USA HQ
2020 Founded
11 Employees
Public company Type
KTTA · NYSE Ticker
Company details
- Status
- Public
- HQ
- Miami Beach, USA
- Founded
- 2020
- Employees
- 11
- Programs
- 3
- Drugs
- 6
- Patents
- 0
PAS-004 Tablets
Phase 1 · small molecule · NF1 Mutation
PAS-004 Tablets for NF1 Mutation is a Phase 1 program (small_molecule) at Pasithea Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code PAS-004-103
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Pasithea Therapeutics
- Phase
- Phase 1
- Modality
- small_molecule
- Indication
- NF1 Mutation
- Status
- active
- Trials
- 1